Melasma is a common pigmentary disorder characterized by grey brown macules and patches on sun exposed skin. Many treatment modalities which include bleaching agents like retinoids, topical corticosteroids or superficial peeling agents have been tried alone or in combinations. Introduction of trenaxamic acid is a new concept. 50 patients clinically diagnosed as melasma after Wood’s lamp examination were enrolled after taking informed consent. All patients were investigated for coagulation profile, complete blood picture and thyroid profile. Each patient was given oral trenaxamic acid 250 mg twice daily after food for 3months along with instructions to apply topical broad spectrum sunscreen three times a day. They were followed up once in a month for another 3 months. MASI score was calculated initially and at each visit. Results were assessed clinically, photographically and by patient satisfaction. Out of 50, 48 patients had excellent improvement. Response was seen within 2 months of initiation of therapy.